nepafenac has been researched along with Malignant Melanoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Garri, DD; Karamysheva, АF; Moiseeva, NI; Saakyan, SV; Tsygankov, АY | 1 |
| Antecka, E; Burnier, MN; Di Cesare, S; Fernandes, BF; Logan, PT; Maloney, SC; Marshall, JC | 1 |
2 other study(ies) available for nepafenac and Malignant Melanoma
| Article | Year |
|---|---|
Assessment of the Chemosensitivity of Uveal Melanoma Cells Ex Vivo.
Topics: Adult; Aged; Antineoplastic Agents; Benzeneacetamides; Busulfan; Cell Proliferation; Cell Survival; Choroid Neoplasms; Deoxycytidine; Diterpenes; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Male; Melanoma; Middle Aged; Phenylacetates; Primary Cell Culture; Retinyl Esters; Tumor Cells, Cultured; Uveal Neoplasms; Valproic Acid | 2020 |
The use of a cyclooxygenase-2 inhibitor (Nepafenac) in an ocular and metastatic animal model of uveal melanoma.
Topics: Animals; Benzeneacetamides; Cyclooxygenase 2 Inhibitors; Melanoma; Models, Animal; Neoplasm Metastasis; Phenylacetates; Rabbits; Uveal Neoplasms | 2007 |